Evaluation of the expression of the stromal cell‐derived factor‐1 alpha (CXCL 12) in psoriatic patients after treatment with Methotrexate

Abstract

CXCL12 might be involved in the progression of psoriasis vulgaris to PsA. MTX therapy downregulated the expression of CXCL12 of the keratinocytes of psoriasis patients. This downregulation was paralleled by decrease in the PASI score. CXCL12 can be used as a biological marker of disease severity of psoriasis patients.